Guobang Pharma (SH:605507) KAIYUAN SECURITIES·2025-10-20 07:50Investment Rating - The investment rating for Guobang Pharmaceutical is maintained as "Buy" [1] Core Insights - The company achieved a revenue of 4.47 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 1.17%. The net profit attributable to the parent company was 670 million yuan, up 15.78% year-on-year, with a net profit margin of 14.94% [4][5] - The company is expected to maintain strong profitability, with projected net profits of 995 million yuan, 1.235 billion yuan, and 1.391 billion yuan for 2025, 2026, and 2027 respectively. The current stock price corresponds to a PE ratio of 12.6, 10.2, and 9.0 for the respective years, indicating high valuation attractiveness [4][5] Financial Performance Summary - For Q3 2025, the company reported a revenue of 1.444 billion yuan, a decrease of 5.39% year-on-year, while the net profit attributable to the parent company increased by 23.17% to 215 million yuan. The gross margin was 27.00%, up 1.64 percentage points [4][5] - The company maintained a research and development expense ratio of 3.43%, a decrease of 0.20 percentage points, indicating improved cost management [5] - The company’s revenue from domestic operations was 1.735 billion yuan (57% of total), while overseas revenue was 1.291 billion yuan (43% of total) as of H1 2025, reflecting a strong global market presence [6] Valuation Metrics - The projected revenue for 2025 is 6.786 billion yuan, with a year-on-year growth of 15.2%. The gross margin is expected to be 24.8%, and the net margin is projected at 14.7% [7][10] - The company’s return on equity (ROE) is forecasted to improve to 11.4% in 2025, with a gradual increase to 12.9% by 2027 [7][10]